Investor relations

The filing of our Registration Statement marks a significant step forward in our path to accessing the public capital markets and vision of bringing the next generation of safe and highly effective cancer therapies to patients.

May 20, 2025

VERAXA Biotech Appoints Rick Austin as Chief Scientific Officer

Industry veteran to support acceleration of key pipeline projects and novel BiTAC antibody formats towards clinical studies.

Upcoming events

View All

Dec 1, 2025

December 1, 2025

hubXchange Antibody Therapeutics Xchange, Munich, Germany

View event

Dec 1, 2025

December 1, 2025

hubXchange Antibody Therapeutics Xchange, Munich, Germany

View event

Nov 17, 2025

November 20, 2025

Jefferies Global Healthcare Conference, London, UK

View event

Nov 17, 2025

November 20, 2025

Jefferies Global Healthcare Conference, London, UK

View event

Nov 11, 2025

November 13, 2025

PEGS Europe, Lisbon, Portugal

View event

Nov 11, 2025

November 13, 2025

PEGS Europe, Lisbon, Portugal

View event

Nov 3, 2025

November 6, 2025

BIO-Europe, Vienna, Austria

View event

Nov 3, 2025

November 6, 2025

BIO-Europe, Vienna, Austria

View event

Latest scientific publications

View All

October 31, 2023

Remodeling the cellular stress response for enhanced genetic code expansion in mammalian cells

Mikhail E. Sushkin, Christine Koehler & Edward A. Lemke

View post

January 1, 2023

Genetic Code Expansion for Site-Specific Labeling of Antibodies with Radioisotopes

Christine Koehler*, Paul F Sauter* , Benedikt Klasen, Christopher Waldmann, Stefanie Pektor, Nicole Bausbacher, Edward A Lemke , Matthias Miederer

View post

January 1, 2021

Synthesis and Evaluation of Novel Ring-Strained Noncanonical Amino Acids for Residue-Specific Bioorthogonal Reactions in Living Cells.

Reinkemeier CD, Koehler C, Sauter PF, Shymanska NV, Echalier C, Rutkowska A, Will DW, Schultz C, Lemke EA

View post